ropinirole has been researched along with Pituitary Neoplasms in 2 studies
Pituitary Neoplasms: Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The first patient, a 46-year-old man, was treated with ropinirole for restless legs syndrome and had lost huge amounts of money in the context of internet-based poker game." | 3.77 | [Pathological gambling induced by dopamine agonists]. ( Connemann, BJ; Gahr, M; Schönfeldt-Lecuona, CJ, 2011) |
| "7 h and exhibited a half-life of 5." | 2.90 | Pharmacokinetics and pharmacodynamics of ropinirole in patients with prolactinomas. ( Bies, R; Cremers, S; Hu, C; Liu, S; Page-Wilson, G; Peters, J; Tsang, A, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, S | 1 |
| Hu, C | 1 |
| Peters, J | 1 |
| Tsang, A | 1 |
| Cremers, S | 1 |
| Bies, R | 1 |
| Page-Wilson, G | 1 |
| Gahr, M | 1 |
| Connemann, BJ | 1 |
| Schönfeldt-Lecuona, CJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole: A Dose Escalation Study of Efficacy and Tolerability[NCT03038308] | Phase 1/Phase 2 | 16 participants (Actual) | Interventional | 2016-09-16 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Radiologic assessment of tumor size before and after treatment will be made by MRI. (NCT03038308)
Timeframe: 6-12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| ROP Intervention | 7 |
Serum prolactin concentrations (PRL levels) were measured in patients at baseline and at follow-up. (NCT03038308)
Timeframe: 6-12 months
| Intervention | percentage of participants (Number) |
|---|---|
| ROP Intervention | 50 |
1 trial available for ropinirole and Pituitary Neoplasms
| Article | Year |
|---|---|
Pharmacokinetics and pharmacodynamics of ropinirole in patients with prolactinomas.
Topics: Adult; Aged; Dopamine Agonists; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Indoles | 2019 |
1 other study available for ropinirole and Pituitary Neoplasms
| Article | Year |
|---|---|
[Pathological gambling induced by dopamine agonists].
Topics: Antiparkinson Agents; Cabergoline; Dopamine Agonists; Ergolines; Gambling; Humans; Indoles; Internat | 2011 |